Brief

On 01/07/2025, the Italian Medicines Agency (AIFA) issued an update regarding AIFA Board approves reimbursement of two medicinal products. The board approved the reimbursement of Kapruvia (difelikefalin) for treating pruritus in adults with chronic kidney disease on dialysis and Prevymis (letermovir) for preventing CMV infection in immunocompromised patients post-transplant, extending its existing indications.

This content is restricted.

Highlights content goes here...

This content is restricted.

Italian Medicines Agency (AIFA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies